CanaQuest Medical Corp CANQF

Biotechnology

CanaQuest Medical Corp is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoidome, including PPAR receptors. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and post-traumatic stress disorder (PTSD). It has created a natural formulation derived from cannabidiol + proprietary API composition. The Company has a drug candidate, CQ-001, positioned for clinical trials targeting epilepsy. Its CQ-001 drug candidate combines cannabidiol (CBD) with essential fatty acids (Omega-3s). In addition, the Company is also focused on developing a nutraceutical version of the formulation, Mentanine, which is scheduled for clinical studies to investigate its potential applications across various indications, paving the way for future clinical trials.